PO-0726: Dose escalation with HDR brachytherapy for intermediate- and high-risk prostate cancer. (May 2017) - Chicas-Sett, R.; Celada, F.; Burgos, J.; Farga, D.; Perez-Calatayud, M.; Roldan, S.; Collado, E.; Ibañez, B.; Perez-Calatayud, J.; Tormo, A.